Pfizer announces commencement of tender offer for all outstanding shares of Encysive Pharmaceuticals Inc.
NEW YORK & HOUSTON - Pfizer Inc today announced the commencement of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., for all outstanding shares of common stock of Encysive Pharmaceuticals Inc. for $2.35 per share, net to the seller in cash.
Pfizer, the US pharmaceuticals group, is in talks to acquire rival Wyeth, a deal that would create new drugs giant with a market value of around $60bn.